Although elevated endogenous GLP-1 levels after bariatric surgery have not previously been linked to reductions in hunger, GLP-1 mimetics have been licensed as anti-obesity agents because of their suppressive effect on food intake (Nauck and Meier, 2018). The gene discussed is GLP1R; the disease is obesity disorder.